Investigating the Validity and Utility of the M-RPDS
Research type
Research Study
Full title
Investigating the Validity and Utility of the Mater-Royal Parkinson’s Disease Cognitive Screening Tool
IRAS ID
347969
Contact name
Martin Dempster
Contact email
Sponsor organisation
Queen's University, Belfast
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
1 years, 3 months, 30 days
Research summary
Cognitive impairment is among the most common non-motor feature of Parkinson’s Disease (PD) (Lawson et al., 2016). Considering the impact cognitive impairment can have on quality of life for individuals living with PD, effectively assessing and monitoring cognition using reliable and valid screening tools is imperative(Arasland et al., 2021). However, it appears there is no gold standard cognitive screening measure for PD and the existing measures recommended by the Parkinson's and Movement Disorder Society (Skorvanek et al., 2018) arguably have some limitations.
The Mater Royal Parkinson’s Disease Cognitive Screener is a novel, free, accessible, comprehensive screening tool which has been developed specifically to assess cognition of individuals living with PD. The proposed study aims to aid the development of the MR-PDCS by exploring test validity and performance within a population of people living with PD.To take part in this study individuals must be between the ages of 50 – 80 years old and have a diagnosis of Parkinson’s Disease which they have lived with for less than 10 years. At this stage, we are recruiting individuals who are otherwise in good general physical and mental health and who do not have significant co-morbidities, significant cognitive decline or dementia.
The study will be conducted primarily in the Royal Victoria Hospital, Belfast Trust, in the Neuropsychology Outpatient Department. If this location is not suitable for a participant, the researchers will aim to facilitate a different Trust location where possible.
Individuals will be invited to take part via their Neurology or Movement disorder team. Following an initial eligibility screening, researchers will arrange a testing session with participants where they will complete the novel MR-PDCS and a comparator screener (ACE-III). Participants will also be invited to take part in a short interview to explore test acceptability. The testing session will last approximately 40 – 60 minutes.
REC name
HSC REC A
REC reference
25/NI/0064
Date of REC Opinion
6 Jun 2025
REC opinion
Further Information Favourable Opinion